Overexpression of cdk4/cyclin D1, a possible mediator of apoptosis and an indicator of prognosis in human primary lung carcinoma

International Journal of Cancer

Volumn 110, Issue 4, 2004, Pages 532-541

  Dobash, Yoh ^a   Goto, Akiteru ^b   Fukayama, Masashi ^b   Abe, Akihisa ^c   Ooi, Akishi ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; cdk4; Cell cycle; Cultured cell; Cyclin D1; Flow cytometry; Immunohistochemistry; Lung carcinoma

Indexed keywords

CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E;

APOPTOSIS; ARTICLE; DNA CONTENT; FLUORESCENCE ACTIVATED CELL SORTING; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; LUNG CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

APOPTOSIS; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASES; DNA, NEOPLASM; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS;

EID: 2442657980     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20167     Document Type: Article

References (57)

1. Morgan DO. Principles of CDK regulation. Nature 1995;374:131-4.
2. Weinberg RA. The retinoblastoma and cell cycle control. Cell 1995; 81:323-30.
3. 1 in mammalian fibroblasts. Science 1993;259:1908-12.
4. Dobashi Y, Kudoh T, Matsumine A, Toyoshima K, Akiyama T. Constitutive overexpression of cdk2 inhibits neuronal differentiation of rat pheochromocytoma PC12 cells. J Biol Chem 1995;270: 23031-7.
5. van Diest PJ, Michalides RJ, Jannink L, van der Valk P, Peterse HL, de Jong JS, Meijer CJ, Baak JP. Cyclin D1 expression in invasive breast cancer. Correlation and prognostic value. Am J Pathol 1995; 150:705-11.
6. Dobashi Y, Shoji M, Jiang SX, Kobayashi M, Kawakubo Y, Kameya T. Active cyclin A-cdk2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am J Pathol 1998; 153:863-72.
7. Fukuse T, Hirata T, Naiki H, Hitomi S, Wada H. Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer. Cancer Res 2000;60:242-4.
8. Handa K, Yamakawa M, Takeda H, Kimura S, Takahashi T. Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prognosis. Int J Cancer 1999;84:225-33.
9. Marone M, Scambia G, Giannitelli C, Ferrandina G, Masciullo V, Bellacosa A, Benedetti-Panici P, Mancuso S. Analysis of cyclin E and cdk2 in ovarian cancer: gene amplification and RNA overexpression. Int J Cancer 1998;75:34-9.
10. 1/S cyclins in human primary lung carcinomas. J Pathol 2003;199:208-20.
11. Noguchi T, Dobashi Y, Minehara H, Itoman M, Kameya T. Involvement of cyclins in cell proliferation and their clinical implications in soft tissue smooth muscle tumors. Am J Pathol 2000;156:2135-47.
12. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992:69:119-28.
13. Qin XQ, Livingston DM, Kaelin WG, Adams PD. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci USA 1994;91:10918-22.
14. O'Hare MJ, Hou ST, Morris EJ, Cregan SP, Xu Q, Slack RS, Parks DS. Induction and modulation of cerebellar granule neuron death by E2F-1. J Biol Chem 2000;275:25358-64.
15. White AE, Livanos EM, Tlsty TD. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev 1994;8:666-77.
16. Kranenburg O, van der Eb A, Zantema A. Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBO J 1996;15:46-54.
17. Dobashi Y, Shoji M, Kondo E, Akiyama T, Kameya T. CDK4, a possible critical regulator of apoptosis in rat pheochromocytoma PC12 cells. Biochem Biophys Res Commun 1998;253:609-13.
18. Davis PK, Dudek SM, Johnson GV. Select alterations in protein kinases and phosphatases during apoptosis of differentiated PC12 cells. J Neurochem 1997;68:2338-47.
19. Shirvan A, Ziv I, Machlin T, Zilkha-Falb R, Melamed E, Barzilai A. Two waves of cyclin B and proliferating cell nuclear antigen expression during dopamine-triggered neuronal apoptosis. J Neurochem 1997;69:539-49.
20. Padmanabhan J, Park DS, Greene LA, Shelanski ML. Role of cell cycle regulatory proteins in cerebellar granule neuron apoptosis. J Neurosci 1999;19:8747-56.
21. Dobashi Y, Shoji M, Kitagawa M, Noguchi T, Kameya T. Simultaneous suppression of cdc2 and cdk2 activities induces neuronal differentiation of PC12 cells. J Biol Chem 2000;275:12572-80.
22. Katayama K, Dobashi Y, Kitagawa M, Kamekura S, Kawai M, Kadoya Y, Kameya T. Overexpression of cdk4/cyclin D1 induces apoptosis in PC12 cells in the presence of trophic support. FEBS Lett 2001;59:382-8.
23. Katayama K, Dobashi Y, Kitagawa M, Kawai M, Kadoya Y, Kameya T. Cdk4/cyclin D1 kinase, a universal and critical regulator of apoptosis. Anticancer Res 2003;23:235-44.
24. Tormanen U, Eerola AK, Rainio P, Vahakangas K, Soini Y, Sormunen R, Bloigu R, Lehto VP, Paako P. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res 1995;55:5595-602.
25. Eerola AK, Roukolainen H, Soini Y, Raunio H, Paakko P. Accelerated apoptosis and low bcl-2 expression associated with neuroendocrine differentiation predict shortened survival in operated large cell carcinoma of the lung. Pathol Oncol Res 1999;5:179-86.
26. Mattern J, Koomagi R, Volm M. Characteristics of long-term survivors of untreated lung cancer. Lung Cancer 2002;36:277-82.
27. Macluskey M, Baillie R, Chandrachud LM, Pendleton N, Schor AM. High levels of apoptosis are associated with improved survival in non-small cell lung cancer. Anticancer Res 2000;20:2123-8.
28. Sanchez RI, Mesia-Vela S, Kauffman FC. Challenges of cancer drug design: a drug metabolism perspective. Curr Cancer Drug Targets 2001;1:1-32.
29. Dobashi Y, Takehana T, Ooi A. Perspectives for cancer therapy: cell cycle blockers and perturbators. Curr Med Chem, 2003;10:2549-58.
30. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. The World Health Organization histologic typing of lung and pleural tumours, 3rd ed. Springer: New York, 1999.
31. Sobin LH, Wittekind CH. International Union Against Cancer. TNM classification of malignant tumours, 5th fully revised ed. New York: Wiley-Liss, 1997. 91-7.
32. Kawarada Y, Miura N, Sugiyama T. Antibody against single-stranded DNA useful for detecting apoptotic cells recognizes hexadeoxynucleotides with various base sequences. J Biochem 1998;123:492-8.
33. Watanabe I, Toyoda M, Okuda J, Tenjo T, Tanaka K, Yamamoto T, Kawasaki H, Sugiyama T, Kawarada, Tanigawa N. Detection of apoptotic cells in human colorectal cancer by two different in situ methods: antibody against single-stranded DNA and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) methods. Jpn J Cancer Res 1999;90:188-93.
34. Shoji M, Dobashi Y, Morinaga S, Jiang SX, Kameya T. Mode of tumor extension and cell proliferation in adenocarcinomas of the lung. Am J Pathol 1999;154:909-18.
35. Dobashi Y, Noguchi T, Nasuno S, Katayama K, Kameya T. CDK inhibitor-associated kinase activity, a possible determinant of malignant potential in smooth muscle tumors of the external soft tissue. Int J Cancer 2001;94:353-62.
36. Mack PC, Gandara DR, Bowen C, Edelman MJ, Paglieroni T, Schnier JB, Gelmann EP, Gumerlock PH. RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma. Clin Cancer Res 1999;5:2596-604.
37. Yokota J, Akiyama T, Fung YK, Benedict WF, Namba Y, Hanaoka M, Wada M, Terasaki T, Shimosato Y, Sugimura T, Terada N. Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. Oncogene 1988;3:471-5.
38. Karpeh MS, Brennan MF, Cance WG, Woodruff JM, Pollack D, Casper ES, Dudas ME, Latres E, Drobnjak M, Cordon-Cardo C. Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas. Br J Cancer 1995;72:986-91.
39. Su YA, Lee MM, Hutter CM, Meltzer PS. Characterization of a highly conserved gene (OS4) amplified with CDK4 in human sarcomas. Oncogene 1997;15:1289-94.
40. An HX, Beckmann MW, Reifenberger G, Bender HG, Niederacher D. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am J Pathol 1999;154:113-8.
41. Wang H, Goode T, Iakova P, Albrecht JH, Timchenko NA. C/EBPalpha triggers proteasome-dependent degradation of cdk4 during growth arrest. EMBO J 2002;21:930-41.
42. Haas-Kogan DA, Kogan SC, Levi D, Dazin P, T'Ang A, Fung YK, Israel MA. Inhibition of apoptosis by the retinoblastoma gene product. EMBO J 1995;14:461-72.
43. L deamidation is a critical switch in the regulation of the response to DNA damage. Cell 2002;111:51-62.
44. Ma D, Zhou P, Harbour JW. Distinct mechanisms for regulating the tumor suppressor and anti-apoptotic function of Rb. J Biol Chem 2003;278:19358-66.
45. Lin BT, Gruenwald S, Morla AO, Lee WH, Wang JY. Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase. EMBO J 1991;10:857-64.
46. Connell-Crowley L, Harper JW, Goodrich DW. CyclinD1/cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell 1997;8:287-301.
47. Brown VD, Phillips RA, Gallie BL. Cumulative effect of phosphorylation of pRB on regulation of E2F activity. Mol Cell Biol 1999;19: 3246-56.
48. Barrientes S, Cooke CA, Goodrich DW. Glutamic acid mutagenesis of retinoblastoma protein phosphorylation sites has diverse effects on function. Oncogene 2000;19:562-70.
49. Arf predisposes mice to tumorigenesis. Nature 2001; 413:86-91.
50. Yeargin J, Haas M. Elevated levels of wild-type p53 induced by radiolabeling of cells leads to apoptosis or sustained growth arrest. Curr Biol 1995;5:423-31.
51. Grossi F, Loprevite M, Chiaramondia M, Ceppa P, Pera C, Ratto GB, Serrano J, Ferrara GB, Costa R, Boni L, Ardizzoni A. Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. Eur J Cancer 2003;39:1242-50.
52. Tan DF, Li Q, Rammath N, Beck A, Wiseman S, Anderson T, al-Salameh A, Brooks J, Bepler G. Prognostic significance of expression of p53 oncoprotein in primary (stage I-IIIa) non-small cell lung cancer. Anticancer Res 2003;23:1665-72.
53. Baksh FK, Dacic S, Finkelstein SD, Swalsky PA, Raja S, Sasatomi E, Luketich JD, Fernando HC, Yousem SA. Widespread molecular alterations present in stage I non-small cell lung carcinoma fail to predict tumor recurrence. Mod Pathol 2003;16:28-34.
54. Lipponen PH, Aaltoma S. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol 1994;173: 333-9.
55. Ghosh M, Crocker J, Morris A. Apoptosis in squamous cell carcinoma of the lung: correlation with survival and clinicopathologic features. J Clin Pathol 2001;54:111-5.
56. Lipponen P, Aaltoma S, Kosma VM, Syrjanen K. Apoptosis in breast cancer as related to histopathologic characteristics and prognosis. Eur J Cancer 1994;30A:2068-73.
57. Shao ZM, Jiang M, Wu J. Inhibition of apoptosis in human breast cancer as related to prognosis. Oncol Rep 1996;3:1183-6.